Bridging the Gap: Index Volume [International Conference on AIDS (12th: 1998: Geneva, Switzerland)]

158 prophylaxis * protease

12th World AIDS Conference

Keyword
for Mycobacterium avi

Abstract--
um co 22167?/Underuse of primary

oviral therapy?/ls MAC necessary in HIV positive indi
e suspension (ATQ) for of Pneumocystis carinii pneu
/Withdrawal of primary against P. carinii and T. gondi
afe to stop primary PCP in patients treated with antiret
methamine for primary of P. carinii pneumonia (PCP)
erosolized pentamidine in the era of combination antiarinii pneumonia (PCP) after HAART in patients with
nostic lab/HAART and result in further cost savings b
dard zidovudine (ZDV) /Risk factors for perinatal HIV
dine (ZDV) for perinatal starting on week 24 in Argenti
us (HIV) post-exposure /Preventability of occupation?/Is antiretroviral MCT provoking increased pregnan
ections/Clarithromycin for MAC in AIDS patients red
T/Discontinue primary regimens in selected HIV-infe
o opportunistic infection /Poor medication adherence
CWs) as post-exposure (PEP) for occupational expos
nting for post-exposure (PEP) following high risk sexu
/Post-sexual exposure (PSEP) with HAART after sex
bination post-exposure (PEP): A prospective study of
ospital/Post-exposure for occupational and sexual e
e workers (HCWs) and after an occupational exposur
I centers/Antiretroviral of occupationally exposed he
ancisco/Post-exposure: Community controversies in
f-house post-exposure team for occupational exposu
etroviral post exposure /Zidovudine and combination
offering post-exposure (PEP) for episodic high-risk s
entions/Post-exposure for sexual risks: Implications f
inicians' post-exposure hotline (PEPLine)/National cl
fit?/Post HIV exposure: Who may benefit?/Post HIV
nd wife/Post-exposure and sexual HIV transmission
pational post-exposure (PEP)/French physicians ex
urvey of the practice of against opportunistic infectio
mplex (MAC) infection in HIV-infected patients with
he cost-effectiveness of for Mycobacterium avium co
e used to target CMV in AIDS patients? Insights fro
IV accidental exposure program in British Columbia,
rage for post-exposure in an urban university hospital
te in a routine penicillin program in Surabaya, Indone
tion of guidelines/MAC: Application of guidelines/MA
ycin 500 mg daily/MAC with clarithromycin 500 mg da
d individuals/Failure of for Pneumocystis carinii pneu
AIDS education among prostituted women in Davao City/The role
rsistently seronegative prostitutes in Nairobi, Kenya/A family stu
rsistently seronegative in Nairobi, Kenya/A family stu
HIV-1 resistant Kenyan /HIV-1 specific mucosal IgA in
es in uninfected Kenyan: Behavioural and immunologic
munication (IEC) among registered with an Sexually Tr
on trial in foreign female (FFPs) in Japan/HIV risk beha
V-1 seropositity among in the Tenere desert, Niger/HI
of reconversion among in Dakar/Experimental activity
ual/bisexual males and in Madrid area (1986-1998)/E
osis for STDs in female, Costa Rica, 1997/Compariso
mong the low income /Condom use and promotion a
S - Profitable activities/ Prostitution - HIV/AIDS - Profitable activi
and information project/ support and information proje
European Network Male (ENMP)/European Network
hnographic research on prostitution in Mahabalipuram/An ethnog

22175
22178
22179
22180
22181
22182
22186
22369
462*/23265
23299
23330
24199
31205
31225
32376
246*/33171
33173
250*/33174
33175
247*/33176
33177
33178
251*/33179
33181
33182
576*/33183
33184
33185
33188
33189
248*/33192
42412
43481
479*/44238
44242
60162
60200
60355
60471
60716
60797
24326
23354
23362
329*/31101
600*/31123
33310
43270
43564
60265
60315
60329
60839
23584
43341
60904
14310
33250
33355
531*/43290
43354
43362
60455
60457
60672
60869
60421
22354
22257
12172
12280
12291
12309
12334
32172

32390
32391
389*/32406
32440

Trials Group (PACTG)/
S, virtually normal now?
AIDS infected patients/
d HIV-1 RNA response/
ents with CMV retinitis/
ffects in an HIV clinic/
enous inhibitor of HIV-1
d protein, viral RNA and
immature HIV-1 during
bility in the presence of
se/Extended benefit of
onferring resistance to
2, ABC) combined with
0 mg) given BID plus a
ed individuals/Study of
tained effectiveness of
etrospective analysis of
olerability and toxicity of
on pattern of the RT and
bination therapy with a
ifornia before and after
odeficiency started on
ong HIV patients taking
novel inhibitor of HIV-1
the resistance of HIV-1
avir after failure of other
h in patients receiving a
tiretroviral therapy with
g treatment including a
s of dimerization HIV-1
ation despite prolonged
Virological response to
TV)-saquinavir (SQV) in
mbination therapy with
tabolic disorders due to
ed nelfinavir/saquinavir
mellitus associated with
erm results of a double
ty of ritonavir and other
s associated with use of
ess of combination with
y of amprenavir, a novel
es of discontinuation of
rance of treatment with
ors/Diabetes and use of
apy after failure of initial
logical effectiveness of
en combined with other
hibitors/Experiences in
nfected children/Use of
atients/Experience with
r?/Is saquinavir a weak
ombination therapy with
women after initiation of
ed patients treated with
ffects of antiretroviral
50 2D6 and 3A4 by HIV
ycemia associated with
ted metabolism by HIV
HIV clinic/Evaluation of
panding the spectrum of
o adherence (ADH) with
Hump" associated with
Discontinuation (D/C) of
mong patients receiving
sons being treated with
uMA) protein by HIV-1
CMV retinitis receiving
ction/lnfluence of HIV
MV disease in the era of
HIV/Impact of indinavir (
esponse to therapy with
onavir-containing dual
g treatment with HIV-1
rst study/Novel double

rapy/Failure of double
V/SQV) combination in
o ritonavir/saquinavir in
e, Italy/Prescriptions of
ment study in the era of

Keyword Abstract -
inhibitor (PI) use in women and c 32444
inhibitors and the end of consens 637*/44183
inhibitor (PI) change within a tripl 60321
inhibitor adherence and HIV-1 R 60363
inhibitor therapy is associated wi 60405
inhibitors: Use and effects in an 60523
protease and peptide derivatives of Vif inhi 377*/11130
of HIV-1 on infectious virion asse 379*/11131
inhibitor treatment or by mutants 11132
inhibitors in vitro/HIV maturation 11133
inhibitor-containing combination 341*/12101
inhibitors in naive patients at the t 12201
inhibitors (PI) in therapy naive pa 12210
inhibitor (PI) compared to 3TC 1 12220
inhibitor combination in Europe ( 290*/12222
inhibitor (PI) therapy (Rx) followi 12231
inhibitor efficacy among patients 12236
inibitor, containing regimens in H 12242
genes in HIV-infected children re 12257
inhibitor in children and adolesce 12262
inhibitors/Mortality and health ca 441*/12264
inhibitors (PI) in March 1996/Cli 440*/12266
inhibitors/Significant increases i 12269
/Anti-HIV-1 activity of and HIV-1 r 12270
inhibitors/Importance of molecul 12277
inhibitors (PI)/Limited efficacy of 12281
inhibitor/Factors associated with 12282
inhibitors/HIV RNA load in blood 12284
inhibitor (PI)/Salvage therapy wi 12285
inhibitors/Peptidic "tongs" constr 12289
inhibitor therapy suggests residu 12293
inhibitors in an HIV clinic cohort/ 12294
inhibitor-naive patients after 72 12295
inhibitor/Virological follow-up of 12297
inhibitor containing regimens/As 12299
inhibitor treatment in a BID regim 12303
inhibitor therapy/Onset diabetes 12308
inhibitor therapy with saquinavir 12313
inhibitors in the presence of hum 12315
inhibitors: Prevalence, clinical se 12319
inhibitors in the treatment of HIV- 12320
inhibitor, in combination with zid 12321
inhibitor (PI) therapy in routine cli 12325
inhibitors in HIV and hepatitis Cv 12326
inhibitors/Diabetes and use of 12327
inhibitor (PI) regimen/Efficacy a 12330
inhibitor therapy in protease inhi 12338
inhibitors (PIs)/ln vitro antiviral a 12339
inhibitor use in patients heavily p 12340
inhibitors in HIV-infected childre 12344
inhibitors in HIV/AIDS patients/E 12346
inhibitor?/Is saquinavir a weak 12348
inhibitors in HIV(+) patients/Tole 12349
inhibitor therapy/Changes in bo 177*/12373
inhibitors/Metabolic changes in 178*/12375
inhibitors (PIs) on serum lipids a 12381
inhibitors/In vitro inhibition of cyt 12382
inhibitor therapy/Hyperglycemia 12387
inhibitors/Prediction of in vivo im 12390
inhibitor-associated hyperglyce 12395
inhibitors-induced lipodistrophy/ 12398
inhibitors/Factors related to adh 12400
inhibitors and use of corticoids oi 12403
inhibitor (PI) therapy: Reasons a 180*/12443
inhibitors/Unconventional medic 14119
inhibitors gambling with high risk 14143
may play a role in cytopathogene 21150
inhibitors/Recurrence of CMV di 16*/22239
inhibitors on hepatitis C viral (HC 22252
inhibitors/Risk of CMV disease i 22258
inhibitor) on HCV viral load in pati 22269
inhibitors in clinical practice/Res 22347
inhibitor regimens may have syn 22350

inhibitors/Efficacy of the combin 22357
combinations-combining indinav 22372
inhibitor therapy as a salvage the 22375
inhibitor (PI) naive and pretreate 22390
inhibitor (PI) experienced patient 22391
inhibitor (PI) antiretroviral (AR) dr 22396
inhibitors/AIDS and palliative ca 22435

ntion among women in
menace of cross border
c/Situation analysis of
women in caste-based
IV/AIDS for women's
s among the women in
rs associated with child
Prevention among male
nomena in Poland/New

and allied groups in Salem, T
in the spread of HIV/AIDS in B
in Bobo Dioulasso, Burkina F
of Rajasthan, India/Impact of
in the Philippines/Preventive
(WIP)/Existing facts, need for
and HIV transmission in Mum
in Paris/Prevention among m
phenomena in Poland/New

or drug trafficking and prostitutions in Karachi, Pakistan/Preval
mbination therapy with protease-inhibitor during six to twenty on
ession after initiation of protease-inhibitors therapy: A long-term f
dren with HIV infection/ Protease inhibitors in children with HIV inf

n New York City (NYC)/
terminants and impact/
en with HIV 1 infection/
al virological response/
m indinavir to nelfinavir/
y housed (H/M) adults/
medication adherence/
e but rarely prescribed/
multiple antiviral drugs/

inhibitors are associated with de
inhibitors among injecting drug u
inhibitor therapy in 19 children wi
inhibitors containing regimens: T
inhibitor-associated hyperglyce
inhibitors (PI) are associated wit
inhibitors and recreational drugs:
inhibitors (PI) in the HIV+ homele
inhibitor therapy in HIV-infected